Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 953, pseudogene (RNU6-953P) is a processed pseudogene derived from the U6 small nuclear RNA (snRNA) gene family. U6 snRNA is a highly conserved and well-studied essential spliceosomal RNA, which plays a catalytic role in RNA splicing as part of the major spliceosome complex[1][3]. However, RNU6-953P itself is a pseudogene, meaning it is a nonfunctional copy that does not produce a functional RNA or protein product and has lost its original biological activity[4]. Pseudogenes such as RNU6-953P can occasionally have regulatory functions at the RNA level—examples in the literature show some pseudogenes producing transcripts that act as microRNA decoys or regulate parental gene expression[2]. Nonetheless, there is no evidence in the literature or public gene databases that RNU6-953P specifically produces an RNA transcript with regulatory, cellular, or disease-related activity. Nor does it represent a known drug target, receptor, enzyme, transporter, or other molecule typically relevant in therapeutic contexts. RNU6-953P is best classified as a noncoding RNA pseudogene, not a druggable or functionally relevant biological target. Notes: - *is_incorrect* is set to true because “RNU6-953P” is not a true therapeutic target; it is a pseudogene and not functionally equivalent to U6 snRNA or other canonical targets. - While *U6 snRNA* is biologically essential, pseudogenes of U6 (such as RNU6-953P) lack this function; assigning disease or drug associations to RNU6-953P would be incorrect in the absence of supporting data. - The general mechanisms by which pseudogenes may impact biological function are summarized, but none of these mechanisms are proven for this specific pseudogene[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 953, pseudogene (RNU6-953P).